Proposed issue of securitiesAnnouncement Summary

Entity name

For personal use only

THE HYDRATION PHARMACEUTICALS COMPANY LIMITED

Announcement Type

New announcement

Date of this announcement 29/3/2022

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

Proposed +issue date 31/5/2023

Refer to next page for full details of the announcementProposed issue of securities

1 / 6

Proposed issue of securities

Part 1 - Entity and announcement details

1.1 Name of +Entity

THE HYDRATION PHARMACEUTICALS COMPANY LIMITED

For personal use only

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type ACN

Registration Number 620385677

1.3 ASX issuer code HPC

1.4 The announcement isNew announcement

1.5 Date of this announcement 29/3/2022

1.6 The Proposed issue is:

A placement or other type of issue

Proposed issue of securities

2 / 6

Proposed issue of securities

Part 7 - Details of proposed placement or other issue

For personal use only

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Will the proposed issue of this +security include an offer of attaching +securities?

No

Existing class

Details of +securities proposed to be issued

ASX +security code and description

HPC : ORDINARY FULLY PAID

Number of +securities proposed to be issued

1,180,833

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Issue of Tranche 1 ordinary shares to Shay Mitchell (or nominee) as part consideration for the provision of brand ambassador services. Number of shares is calculated as USD$250,000 converted to AUD using the exchange rate immediately prior to the date of the agreement, divided by the 10-day VWAP immediately before the date of the agreement.

For more information, refer to the ASX announcement lodged today.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities 332,995.000000

Will these +securities rank equally in all respects from their issue date with

Proposed issue of securities

3 / 6

Proposed issue of securities

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

For personal use only

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Will the proposed issue of this +security include an offer of attaching +securities?

No

Existing class

Details of +securities proposed to be issued

ASX +security code and description

HPC : ORDINARY FULLY PAID

Number of +securities proposed to be issued

1,180,833

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Issue of Tranche 2 ordinary shares to Shay Mitchell (or nominee) as part consideration for the provision of brand ambassador services to be issued one (1) year after the first public usage of the content created under the Agreement. Number of shares is calculated as USD$250,000 converted to AUD using the exchange rate immediately prior to the calculation date, divided by the 10-day VWAP immediately before the calculation date. Note: the number of shares included in this Appendix is an estimate only and has been calculated on the basis of the current exchange rate and current 10-day VWAP. Accordingly, the number of Tranche 2 shares is expected to change.

For more information, refer to the ASX announcement lodged today.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities 332,995.000000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Proposed issue of securities

4 / 6

Proposed issue of securities

Part 7C - Timetable

7C.1 Proposed +issue date

31/5/2023

For personal use only

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Approx 1,180,833 Tranche 1 shares on or before 5 April 2022.

Approx 1,180,833 Tranche 2 shares on or before 31 May 2023. In the event that the Company does not have sufficient placement capacity at the time of issue, the Company will issue the maximum number of shares possible and seek shareholder approval for the remainder of the Tranche 2 shares.

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No

  • 7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

    No

  • 7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

    No

  • 7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

Yes

7D.4a Please enter the number and +class of the +securities subject to +voluntary escrow and the date from which they will cease to be subject to +voluntary escrow 75% of Tranche 1 shares and Tranche 2 shares will be subject to voluntary escrow until 14 December 2023. 25% of Tranche 1 shares and Tranche 2 shares will be subject to voluntary escrow until 14 June 2023.

Part 7E - Fees and expenses

  • 7E.1 Will there be a lead manager or broker to the proposed issue?

    No

  • 7E.2 Is the proposed issue to be underwritten?

No

Proposed issue of securities

5 / 6

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Hydration Pharmaceuticals Co. Ltd. published this content on 29 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 March 2022 01:33:05 UTC.